Shares of Edwards Lifesciences Corporation (NYSE:EW) have been given a consensus rating of “Buy” by the twenty-four brokerages that are currently covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $121.25.

Several research analysts have weighed in on EW shares. Stifel Nicolaus upped their price target on Edwards Lifesciences Corporation from $114.00 to $118.00 and gave the stock a “buy” rating in a research note on Wednesday, April 26th. Royal Bank Of Canada upped their price target on Edwards Lifesciences Corporation from $116.00 to $120.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 26th. Jefferies Group LLC restated a “buy” rating on shares of Edwards Lifesciences Corporation in a research note on Wednesday, April 26th. Vetr downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “hold” rating and set a $110.88 price target for the company. in a research note on Wednesday, April 26th. Finally, Goldman Sachs Group, Inc. (The) started coverage on Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price target for the company.

Shares of Edwards Lifesciences Corporation (EW) traded down 0.27% during midday trading on Tuesday, reaching $116.16. 976,924 shares of the company’s stock traded hands. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75. The stock’s 50-day moving average price is $117.28 and its 200 day moving average price is $104.65. The firm has a market capitalization of $24.53 billion, a PE ratio of 35.23 and a beta of 0.63.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million during the quarter, compared to the consensus estimate of $839.16 million. During the same period in the prior year, the company posted $0.76 EPS. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current fiscal year.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 25,000 shares of the stock in a transaction on Friday, August 4th. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Patrick B. Verguet sold 22,631 shares of the stock in a transaction on Friday, May 19th. The stock was sold at an average price of $113.16, for a total value of $2,560,923.96. The disclosure for this sale can be found here. In the last quarter, insiders sold 150,512 shares of company stock worth $17,360,159. Insiders own 2.13% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Edwards Lifesciences Corporation by 2.5% in the first quarter. Vanguard Group Inc. now owns 20,341,668 shares of the medical research company’s stock worth $1,913,541,000 after buying an additional 505,725 shares during the period. BlackRock Inc. increased its stake in shares of Edwards Lifesciences Corporation by 2,184.9% in the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock worth $1,317,326,000 after buying an additional 13,390,818 shares during the period. State Street Corp increased its stake in shares of Edwards Lifesciences Corporation by 1.7% in the first quarter. State Street Corp now owns 9,388,994 shares of the medical research company’s stock worth $883,219,000 after buying an additional 157,844 shares during the period. Alliancebernstein L.P. increased its stake in shares of Edwards Lifesciences Corporation by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock worth $598,890,000 after buying an additional 1,459,921 shares during the period. Finally, Ameriprise Financial Inc. increased its stake in shares of Edwards Lifesciences Corporation by 17.4% in the first quarter. Ameriprise Financial Inc. now owns 5,737,459 shares of the medical research company’s stock worth $539,685,000 after buying an additional 850,168 shares during the period. Institutional investors and hedge funds own 84.15% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of US & international copyright & trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/08/edwards-lifesciences-corporation-ew-receives-consensus-rating-of-buy-from-analysts.html.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.